BioStock: Strong first half of the year for Elicera
Elicera Therapeutics’ interim report for the first half of 2025 spotlights promising results from its CARMA study, where four out of six patients showed complete metabolic response response (no active disease). Backed by strengthened finances, the company is preparing for critical data readouts the coming year.
Read the article at biostock.se:
Strong first half of the year for Elicera
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/